deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT01927731

Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

Safety and Efficacy of Eltrombopag in Patients Undergoing Cord Blood or Haploidentical Bone Marrow Transplantation

Sponsor: M.D. Anderson Cancer Center

Conditions Bone Marrow Transplantation Recipient Cord Blood Transplant Recipient Hematopoietic Cell Transplantation Recipient
Interventions Eltrombopag Olamine Laboratory Biomarker Analysis
Updated 16 times since 2017 Last updated: Mar 27, 2024 Started: Oct 14, 2013 Primary completion: Jun 6, 2023 Completion: Jun 6, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Bone Marrow Transplantation Recipient and Cord Blood Transplant Recipient and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 16 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Dec 2018 · 4 months · monthly snapshot~Dec 2018 – ~Feb 2020 · 14 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2022 · 13 months · monthly snapshot~Mar 2022 – ~Nov 2022 · 8 months · monthly snapshot~Nov 2022 – ~Mar 2023 · 4 months · monthly snapshot~Mar 2023 – ~Jul 2023 · 4 months · monthly snapshot~Jul 2023 – ~May 2024 · 10 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jul 2023 — May 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Mar 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 11 earlier versions

  1. Nov 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Feb 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Dec 2018 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Aug 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  8. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. May 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  10. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations